Mission Focused Team

OUR COMPANY

Since 2015, BiomX has been discovering and developing innovative microbiome-based therapeutics to prevent and treat cancer, IBD, and skin disorders that stem from microbiome dysbiosis. The Company’s microbiome modulation platform uses cutting-edge science, research, and licensed technology created by its founders, Professor Rotem Sorek, Ph.D., and Prof. Eran Elinav, M.D./Ph.D., both of The Weizmann Institute of Science; and Professor Timothy K. Lu, M.D./Ph.D., of The Massachusetts Institute of Technology.

Investors in the Company include OrbiMed Israel Incubator LP, Johnson & Johnson Development Corporation Inc., Takeda Ventures, Inc., Seventure Partners, Mirae Asset Global Investments, and SBI. Microbiome is a new and fast-developing field at the junction of nutrition and pharmaceuticals. BiomX offer a complete solution ranging from target discovery to therapeutic compounds. We have unique capabilities to modulate the microbiome and address dysbiosis through adding or eradicating bacteria with both native phages and synthetic phage that we engineer.

OUR INVESTORS

EXECUTIVE TEAM

Jonathan Solomon

CEO and Board Member

Prior to his role in Biomx, Mr. Solomon was a co-founder, president, and CEO of ProClara (formerly NeuroPhage), which is pioneering an approach to treating neurodegenerative diseases. Under his leadership, the company raised more than $100 million and launched an ongoing clinical trial related to Alzheimer’s disease. Prior to that, he was selected to participate in the elite Israeli Defense Forces ‘Talpiot’ program, graduated as class valedictorian, and served for 10 years in a classified military unit. Mr. Solomon holds a B.Sc. magna cum laude in Physics and Mathematics from the Hebrew University, an M.Sc. summa cum laude in Electrical Engineering from Tel Aviv University, and an M.B.A. with honors from the Harvard Business School.

Naomi B. Zak, PhD.

PRESIDENT & COO

Dr. Zak holds a Ph.D. from Harvard Medical School and completed a postdoctoral fellowship at the Weizmann Institute of Science. Dr. Zak has over 15 years of leadership experience in the biotech industry in a range of executive capacities, including: manager of regulatory affairs at Chiasma, a clinical stage company developing oral formulations for medications currently administered parenterally; and director of R&D in both IDgene, a gene discovery company, and CellCure, a clinical stage company developing human embryonic stem cell based therapies. More recently, she served as interim CEO of ProtAb and as CEO of SCTherapeutics. Dr. Zak has led company launching activities, target indication assessment, establishment of research platforms, and product development activities.

Assaf Oron

CBO

Assaf Oron has served as chief business officer since January 2017. Prior to this position, he served for over a decade at Evogene (NYSE:EVGN), an agriculture biotechnology company which utilizes a proprietary integrated technology infrastructure to enhance seed traits underlying crop productivity.  At Evogene, he worked in various roles such as executive vice president of corporate development and executive vice president of strategy and business development. From 2004 to 2006, Mr. Oron served as CEO of ChondroSite Ltd., a biotechnology company that develops engineered tissue products in the field of orthopedics. From 1999 to 2003, Mr. Oron was a senior project manager and strategic consultant at POC Ltd., a leading Israeli management consulting company. Mr. Oron holds an M.Sc. in Biology (bioinformatics) and a B.Sc. in Chemistry and Economics, both from Tel Aviv University.

Sigal Fattal

CFO

Before joining Biomx, Ms. Fattal served as an executive officer, CFO (May 2013 to January 2016), and vice president of finance (October 2012 to May 2013) of Evogene Ltd. Previously, Ms. Fattal was the CFO and executive vice president of Transpharma Medical Ltd. Prior to joining TransPharma, she was the director of finance (2001 to 2004) and the corporate controller (1998 to 2000) at ECtel Ltd. (Nasdaq: ECTX). Ms. Fattal has extensive experience working in the capital markets, including IPO, PIPE, and M&A transactions, as well as managing financial, operational, and business activities. Ms. Fattal holds a B.A. in Accounting and Economics with honors and an M.B.A., both from Tel Aviv University.

BOARD OF DIRECTORS

Karen Hong, PhD.

Prior to Takeda Ventures, Dr. Hong was a Partner at ProQuest Investments, a healthcare dedicated venture fund, where she worked for fifteen years, deploying three funds and supporting all fund operations. She and her team at ProQuest guided over thirty investments to a successful exit. Dr. Hong currently serves on the Board of Directors of Palleon Pharmaceuticals, BiomX, and Emendo Biotherapeutics and is a Board Observer to Ribon Therapeutics, Encycle Therapeutics, and Arcellx. Previously, she represented ProQuest as a Director of Agile Therapeutics (Nasdaq: AGRX) and Clarus Therapeutics, and as a Board Observer to Mevion Medical Systems, Mersana Therapeutics (Nasdaq:MRSN), BioRexis Pharmaceutical Corp. (acquired by Pfizer), Gloucester Pharmaceuticals (acquired by Celgene) and LEAD Therapeutics (acquired by BioMarin), among others. She brings over twenty years of experience in life science investing and biomedical research. Prior to joining ProQuest, Dr. Hong led multiple research projects in mammalian cancer genetics in the laboratory of Dr. Eric Lander at the Whitehead Institute for Biomedical Research, identifying one of the first genetic modifier genes. Dr. Hong received a B.S. in chemistry and a B.A. in molecular biology from the University of California at Berkeley, where she graduated with honors and as a member of Phi Beta Kappa. She received a Ph.D. in biology from the Massachusetts Institute of Technology. Personal interests include skiing and biking with her husband and two children.

Erez Chimovits

Erez Chimovits is a senior managing director at Orbimed Healthcare Fund Management. Mr. Chimovits has 14 years of operational experience, including 10 years of senior managerial experience in public companies. Prior to joining OrbiMed, Mr. Chimovits was the CEO of NasVax (TASE:NSVX), which acquired Protea and struck agreements with GlaxoSmithKline and Novartis. Previously, Mr. Chimovits spent more than seven years with Compugen (Nasdaq:CGEN), as president of Compugen USA Inc., and as executive vice president of commercial operations. At Compugen, he had P&L responsibility for more than 100 people and led multiple transactions with companies including J&J, Novartis, Teva, Abbott, and Medarex. Mr. Chimovits earned his M.B.A., M.Sc. in Microbiology, and B.Sc. from Tel Aviv University.

Zeev Zehavi

Zeev Zehavi is vice president of venture investments for Johnson & Johnson Innovation – JJDC, Inc., which he joined in 1999. Mr. Zehavi’s background covers an extensive array of health care and related businesses. He spent over 10 years with Teva Pharmaceutical Industries, Ltd., including a five-year assignment as president of the bulk chemical business in North America. He returned to Israel as president of Clal Pharmaceutical Industries (CPI) for four years before starting his own medical device and pharmaceutical start-up consulting business, Pharma Zee, Ltd., where he initiated contacts with various Johnson & Johnson companies. Mr. Zehavi holds a B.Sc. from the Hebrew University of Jerusalem and an M.B.A. in Marketing and Finance from Tel Aviv University.

Henk Brulleman

Henk Brulleman studied Business Economics at the Free University in Amsterdam. He started his career at Royal Dutch Shell and rose to the position of deputy chief investment officer. He then became a partner at Numeric Investors LLC, a Boston-based quantitative equity management firm, where he co-managed portfolios with a combined value of $3 billion and  handled client relations, marketing, and modeling. After retiring from Numeric, he built a portfolio of several equity and convertible debt stakes, predominantly in the field of life sciences, pharmaceuticals, and medical technology. After five years of retirement, he recently joined Wolkers & Co, a multi-family fiduciary asset management office, as a partner.

SCIENTIFIC FOUNDERS

Prof. Rotem Sorek

Prof. Sorek leads the Microbial Genomics group in the Department of Molecular Genetics at the Weizmann Institute of Science. He is a world leader in phage genomics and CRISPR research,
and also develops techniques for high resolution understanding of microbial transcriptomics and metatranscriptomics. Prof. Sorek holds a Ph.D. in Human Genomics from Tel Aviv University, and in his postdoc, studied microbial metagenomics at the Lawrence Berkeley National Laboratory. Prior to joining the Weizmann Institute, Prof. Sorek headed the Genomics Research Group at Compugen (Nasdaq:CGEN). Prof. Sorek is also an author of numerous scientific publications in top-tier journals, and an inventor of more than 35 patents. He has received multiple awards, including the 2012 Rubinowitz-Grossman Prize in Microbiology, the 2013 Teva Founders Award for young scientists, and the 2014 FEBS Anniversary Prize. In 2015, Prof. Sorek was elected as a member of the European Academy of Microbiology.

Prof. Eran Elinav

Prof. Elinav is a senior scientist leading a research group in the Immunology Department at the Weizmann Institute of Science. Prof. Elinav has over 110 published articles and received several awards for his work, including the 2013 Alon Prize and the 2015 Rappaport Prize for outstanding biomedical research. Before joining the Weizmann Institute, Prof. Elinav held an independent research position at the Institute for Gastroenterology and Liver Disease at the Tel Aviv Sourasky Medical Center. Prof. Elinav completed his M.D. at the Hebrew University of Jerusalem Hadassah Medical Center summa cum laude, followed by internship, residency, clinical, and research positions at the Tel Aviv Medical Center Gastroenterology Institute. Prof. Elinav also has a Ph.D. in immunology from the Weizmann Institute of Science and served in a postdoctoral fellowship at the Yale University School of Medicine.

Prof. Timothy K. Lu

Prof. Lu is an associate professor leading the Synthetic Biology Group in the Department of Electrical Engineering and Computer Science and the Department of Biological Engineering at MIT. Prof. Lu graduated with an S.B. and M.Eng. from MIT, and an M.D./Ph.D. from the Harvard-MIT Health Sciences and Technology program. He is also a core member of the MIT Synthetic Biology Center and a co-founder of multiple biotechnology companies that develop innovative diagnostic and therapeutic technologies for human health. Prof. Lu is a recipient of the ACS Synthetic Biology Young Investigator Award, the Biochemical Engineering Journal Young Investigator Award, the NIH New Innovator Award, the Presidential Early Career Award for Scientists and Engineers, and the Ellison Medical Foundation New Scholar in Aging Award, among others.

SCIENTIFIC ADVISORY

Richard A. Flavell, PhD.

Dr. Flavell is a Sterling Professor of Immunobiology at Yale University and an Investigator at the Howard Hughes Medical Institute. He received his B.Sc. and Ph.D. from the University of Hull and performed postdoctoral work with Piet Borst and Charles Weissmann. Dr. Flavell was also first assistant professor (equivalent) at the University of Amsterdam (1974-79); head of the Laboratory of Gene Structure and Expression at the National Institute for Medical Research, Mill Hill, London (1979-82); and president and chief scientific officer of Biogen Research Corporation (1982-88). Dr. Flavell is a fellow of the Royal Society and a member of EMBO, the National Academy of Sciences, and the National Academy of Medicine. Dr. Flavell was also the founding chairman of Yale’s Department of Immunobiology, has published more than 1,000 peer reviewed papers, and is one of the world’s most cited immunologists.

Michael Koeris, PhD.

Dr. Koeris is the co-founder and CEO of Sample6, a leading food-safety diagnostics provider using engineered bacteriophages to deliver the world’s first on-site, in-shift bacterial pathogen detection system. Dr. Koeris ideated and instantiated the company’s synthetic biology engineering platform, and protected product lines and manufacturing processes with 15+ patents and application portfolios. The company’s technology originated in Jim Collins’ Synthetic Biology laboratory at MIT and was expanded to include key new inventions enabling a first-in-class phage genome engineering patent for bacteriophages. This novel approach, using yeast-based recombineering, allows the assembly of modified genomes and the addition of modifications post-assembly in yeast. Dr. Koeris also worked at McKinsey & Company and Flagship Ventures, and in Jim Collins’ lab, focusing on bacterial resistance mechanisms, for his Ph.D. He remains a visiting scholar at MIT.

LEARN MORE ABOUT BIOMX MISSION FOR HEALTH

OUR PARTNERS